PROCEPT BioRobotics Corporation reported $337M of revenue over the trailing twelve months, +23% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $337M (to Q2 2026). Net income: −$110M, trailing twelve months to Q2 2026. Free cash flow: −$85M, trailing twelve months to Q2 2026. Operating margin: −34%, trailing twelve months to Q2 2026.

PRCTPROCEPT BioRobotics Corporation

Healthcare

$18.40-51% 1Y

$18.40

$16.6952 weeks$39.15

PRCT as reported

PROCEPT BioRobotics Corporation reported $337M of revenue over the trailing twelve months, +23% on the year before. 10 reported series are charted on this page, each one as filed.

$337M

Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before

Net income: −$110M
Net income · +30% year on year · trailing twelve months to Q2 2026
Free cash flow: −$85M
Free cash flow · −4.9% year on year · trailing twelve months to Q2 2026
Operating margin: −34%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PRCT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$337M	+23%	Q2 2026
Net income	−$110M	+30%	Q2 2026
EPS	−$1.94	+26%	Q2 2026
Gross margin	64%	n/a	Q2 2026
Operating margin	−34%	n/a	Q2 2026
Net margin	−33%	n/a	Q2 2026
ROE	−28%	n/a	Q2 2026
ROA	−20%	n/a	Q2 2026
ROIC	−57%	n/a	Q2 2026
Free cash flow	−$85M	−4.9%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.